162 related articles for article (PubMed ID: 38016003)
21. Effects of benralizumab in a population of patients affected by severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: a real life study.
Santomasi C; Buonamico E; Dragonieri S; Iannuzzi L; Portacci A; Quaranta N; Carpagnano GE
Acta Biomed; 2023 Feb; 94(1):e2023028. PubMed ID: 36786266
[TBL] [Abstract][Full Text] [Related]
22. New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis.
Striz I; Golebski K; Strizova Z; Loukides S; Bakakos P; Hanania NA; Jesenak M; Diamant Z
Clin Sci (Lond); 2023 May; 137(9):727-753. PubMed ID: 37199256
[TBL] [Abstract][Full Text] [Related]
23. Benefits of biologic therapy administered for asthma on co-existent chronic rhinosinusitis: A real-world study.
Bajpai S; Marino MJ; Rank MA; Donaldson AM; O'Brien EK; Lal D
Int Forum Allergy Rhinol; 2021 Aug; 11(8):1152-1161. PubMed ID: 33527730
[TBL] [Abstract][Full Text] [Related]
24. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
Weinstein SF; Katial RK; Bardin P; Korn S; McDonald M; Garin M; Bateman ED; Hoyte FCL; Germinaro M
J Allergy Clin Immunol Pract; 2019 Feb; 7(2):589-596.e3. PubMed ID: 30193936
[TBL] [Abstract][Full Text] [Related]
25. Biologics for chronic rhinosinusitis.
Chong LY; Piromchai P; Sharp S; Snidvongs K; Webster KE; Philpott C; Hopkins C; Burton MJ
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013513. PubMed ID: 33710614
[TBL] [Abstract][Full Text] [Related]
26. Atopic profile of patients failing medical therapy for chronic rhinosinusitis.
Tan BK; Zirkle W; Chandra RK; Lin D; Conley DB; Peters AT; Grammer LC; Schleimer RP; Kern RC
Int Forum Allergy Rhinol; 2011; 1(2):88-94. PubMed ID: 21731824
[TBL] [Abstract][Full Text] [Related]
27. Biologics for chronic rhinosinusitis.
Chong LY; Piromchai P; Sharp S; Snidvongs K; Philpott C; Hopkins C; Burton MJ
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD013513. PubMed ID: 32102112
[TBL] [Abstract][Full Text] [Related]
28. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry.
Canonica GW; Malvezzi L; Blasi F; Paggiaro P; Mantero M; Senna G; Heffler E;
Respir Med; 2020 May; 166():105947. PubMed ID: 32250875
[TBL] [Abstract][Full Text] [Related]
29. Chronic Rhinosinusitis With Nasal Polyps: Quality of Life in the Biologics Era.
Mullol J; Azar A; Buchheit KM; Hopkins C; Bernstein JA
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1434-1453.e9. PubMed ID: 35306180
[TBL] [Abstract][Full Text] [Related]
30. Clinical and cytokine patterns of uncontrolled asthma with and without comorbid chronic rhinosinusitis: a cross-sectional study.
Huang K; Li F; Wang X; Yan B; Wang M; Li S; Yu W; Liu X; Wang C; Jin J; Zhang L
Respir Res; 2022 May; 23(1):119. PubMed ID: 35546400
[TBL] [Abstract][Full Text] [Related]
31. Targeted Molecular Therapies in Allergy and Rhinology.
Damask CC; Ryan MW; Casale TB; Castro M; Franzese CB; Lee SE; Levy JM; Lin SY; Lio PA; Peters AT; Platt MP; White AA
Otolaryngol Head Neck Surg; 2021 Jan; 164(1_suppl):S1-S21. PubMed ID: 33138725
[TBL] [Abstract][Full Text] [Related]
32. Impact of type 2 targeting biologics on acute exacerbations of chronic rhinosinusitis.
Patel GB; Kudlaty EA; Guo A; Yeh C; Kim MS; Price CPE; Conley D; Grammer LC; Kalhan R; Kern RC; McGrath KG; Tan BK; Rosenberg SR; Schleimer RP; Smith SS; Stevens WW; Welch KC; Peters AT
Allergy Asthma Proc; 2021 Sep; 42(5):417-424. PubMed ID: 34474711
[No Abstract] [Full Text] [Related]
33. Prevalence and Severity Distribution of Type 2 Inflammation-Related Comorbidities Among Patients with Asthma, Chronic Rhinosinusitis with Nasal Polyps, and Atopic Dermatitis.
Khan AH; Gouia I; Kamat S; Johnson R; Small M; Siddall J
Lung; 2023 Feb; 201(1):57-63. PubMed ID: 36808551
[TBL] [Abstract][Full Text] [Related]
34. [Experience with dupilumab in the treatment of chronic rhinosinusitis with nasal polyps].
Boiko NV; Stagnieva IV; Lodochkina OE; Kurbatova NV
Vestn Otorinolaringol; 2023; 88(4):46-53. PubMed ID: 37767590
[TBL] [Abstract][Full Text] [Related]
35. Clinical factors associated with acute exacerbations of chronic rhinosinusitis.
Kwah JH; Somani SN; Stevens WW; Kern RC; Smith SS; Welch KC; Conley DB; Tan BK; Grammer LC; Yang A; Schleimer RP; Peters AT
J Allergy Clin Immunol; 2020 Jun; 145(6):1598-1605. PubMed ID: 32004523
[TBL] [Abstract][Full Text] [Related]
36. The Severe Asthma Network in Italy: Findings and Perspectives.
Heffler E; Blasi F; Latorre M; Menzella F; Paggiaro P; Pelaia G; Senna G; Canonica GW;
J Allergy Clin Immunol Pract; 2019; 7(5):1462-1468. PubMed ID: 30368004
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
38. EUFOREA consensus on biologics for CRSwNP with or without asthma.
Fokkens WJ; Lund V; Bachert C; Mullol J; Bjermer L; Bousquet J; Canonica GW; Deneyer L; Desrosiers M; Diamant Z; Han J; Heffler E; Hopkins C; Jankowski R; Joos G; Knill A; Lee J; Lee SE; Mariën G; Pugin B; Senior B; Seys SF; Hellings PW
Allergy; 2019 Dec; 74(12):2312-2319. PubMed ID: 31090937
[TBL] [Abstract][Full Text] [Related]
39. Impact of Gastroesophageal Reflux Disease on Mucosal Immunity and Atopic Disorders.
Hait EJ; McDonald DR
Clin Rev Allergy Immunol; 2019 Oct; 57(2):213-225. PubMed ID: 30206783
[TBL] [Abstract][Full Text] [Related]
40. Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status.
Gevaert P; Mullol J; Saenz R; Ko J; Steinke JW; Millette LA; Meltzer EO
Ann Allergy Asthma Immunol; 2024 Mar; 132(3):355-362.e1. PubMed ID: 37951571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
